Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | XDH | P47989 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60939 | 0.83 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHALDH1A1 | |
| SCHEMBL3876365 | 0.82 | KMT2A (0.73) | KMT2AKDM4EMEN1XDHALDH1A1 | |
| SCHEMBL4700651 | 0.81 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHLMNA | |
| SCHEMBL3871259 | 0.81 | KMT2A (1.00) | KMT2AKDM4EMEN1XDHPTGS2 | |
| SCHEMBL1143771 | 0.81 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHLMNA | |
| SCHEMBL1456317 | 0.81 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHLMNA | |
| SCHEMBL3873109 | 0.81 | KMT2A (0.67) | KMT2AKDM4EMEN1XDHALDH1A1 | |
| SCHEMBL6071143 | 0.79 | KMT2A (0.69) | KMT2AKDM4EMEN1XDHALDH1A1 | |
| SCHEMBL3871978 | 0.78 | KMT2A (0.62) | KMT2AKDM4EMEN1XDHALDH1A1 | |
| SCHEMBL31734506 | 0.77 | KMT2A (0.66) | KMT2AKDM4EMEN1XDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827444-B1 | MNK1 OR MNK2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2009-06-25 | — | — | US | disclosed |
| EP-1827444-A2 | MNK1 OR MNK2 INHIBITORS | DeveloGen Aktiengesellschaft (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066937-A2 | MNK1 OR MNK2 INHIBITORS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | NEK9, CMPK1, NEK2 | KMT2A 877/4885KDM4E 2821/4885MEN1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.